Evaluation of Effectiveness and Safety of DESyne in Routine Clinical Practice; A Multicenter, Prospective Observational Study
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Novolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms IRIS-DESYNE
- 30 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 Planned End Date changed from 1 Jun 2020 to 1 Jun 2025.
- 15 Jun 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2021.